Non-destructive 3D pathology and analysis for precision therapies
Speaker: Jonathan T.C. Liu, PhD
Professor of Pathology and, by courtesy, of Bioengineering
Director, Molecular Biophotonics and Analytics Lab, Stanford University
Abstract
We are developing non-destructive slide-free 3D pathology methods for clinical decision support and surgical guidance. In comparison to conventional slide-based pathology, 3D pathology provides: (1) vastly greater sampling of tissue specimens including whole biopsies and surgical margins, (2) volumetric imaging of cell distributions and 3D tissue structures that are prognostic and predictive, and (3) a non-destructive and reversible workflow that preserves valuable specimens for downstream molecular assays. Due to the immense size of feature-rich 3D pathology datasets, new challenges exist in terms of data management, human visualization, and computer-aided interpretation. We have been working on a full stack of technologies to facilitate the clinical adoption of 3D pathology, from sample preparation (e.g. reversible optical clearing and fluorescence labeling), high-throughput imaging with open-top light-sheet (OTLS) microscopes developed in our lab, to data processing and AI-based image triage and analysis. For AI analyses, we are developing both traditional machine classifiers based on intuitive “hand-crafted” 3D features, and deep-learning classifiers based on sub-visual 3D features. Our non-destructive large-volume digital pathology methods are synergistic with radiology and molecular assays, which collectively have the potential to improve treatment decisions for diverse patient populations.
Biography
Dr. Jonathan Liu is a professor in the department of pathology and of bioengineering at Stanford University, where his molecular biophotonics and analytics laboratory develops high-resolution optical-imaging devices and AI-driven computational pipelines for guiding treatment decisions. Dr. Liu received his B.S.E. degree at Princeton and his M.S. and Ph.D. degrees in mechanical engineering at Stanford. He was a postdoc and instructor within the Molecular Imaging Program at Stanford (MIPS) before transitioning to faculty positions at Stony Brook University (2010 – 2014) and the University of Washington in Seattle (2014 – 2025). Dr. Liu is a co-founder and board member of Alpenglow Biosciences Inc., which has commercialized the non-destructive 3D pathology technologies developed in his lab. Dr. Liu’s work is funded by the NIH, DoD, NSF, ARPA-H and various foundations.